TargetMol

Cytembena

Product Code:
 
TAR-T27112
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27112-1mg1mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27112-5mg5mg£239.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27112-10mg10mg£319.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27112-25mg25mg£541.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27112-50mg50mg£697.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27112-100mg100mg£946.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27112-500mg500mg£1,821.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Cytembena causes a rapid and extensive inhibition of DNA biosynthesis in therapeutic doses.
CAS:
21739-91-3
Formula:
C11H8BrNaO4
Molecular Weight:
307.075
Pathway:
Cell Cycle/Checkpoint|DNA Damage/DNA Repair
Purity:
0.98
SMILES:
[Na+].COc1ccc(cc1)C(=O)C(Br)=C/C([O-])=O
Target:
DNA/RNA Synthesis

References

1. Jackson RC, Taylor GA, Harrap KR. The reaction of Cytembena with cellular thiol compounds. Neoplasma. 1976;23(4):355-62. PubMed PMID: 1036760. 2. Sch?ck O, Grafnetterov? J, Sotorn?k I. Pharmacokinetics of Cytembena in chronic renal impairment. Neoplasma. 1976;23(2):161-70. PubMed PMID: 947088. 3. Falkson HC, Falkson G. Phase II trial of cytembena in patients with advanced ovarian and breast cancer. Cancer Treat Rep. 1976 Nov;60(11):1655-8. PubMed PMID: 1037286. 4. Jackson RC, Taylor GA, Harrap KR. Aspects of the biochemical pharmacology of cytembena. Neoplasma. 1975;22(3):259-68. PubMed PMID: 1080553.